Untitled

Abstract

Hematopoietic stem cell transplantation is arguably one of the most significant therapeutic measures initiated in the recent era, however this therapeutic entity from the outset was significantly limited by HLA matched donor availability. The advent of haploidentical stem cell transplantation with recently improving outcomes and reduced graft failure rates has provided the much needed boom to this aspect of modern day therapeutics by expanding the donor pool and reducing the wait time for a stem cell transplant which is prognostically important especially in aggressive leukemia's and lymphomas.